HutchMed and Innovent Announce Positive Results for Fruquintinib and Sintilimab in Renal Cell Carcinoma Trial
Chinese companies HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) and Innovent Biologics, Inc. (HKG: 1801)...
HutchMed
HutchMed’s Orpathys Approved for Expanded NSCLC Indication in China
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) has announced that the National Medical Products Administration...
HutchMed’s Orpathys Receives Priority Review for NSCLC Treatment in China
HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) has announced that the China National Medical Products...
HutchMed to Divest 45% Stake in Shanghai Hutchison Pharmaceuticals for $608 Million
China-based HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) has reached an agreement to divest its...
CDE Indicates Priority Review for Boehringer Ingelheim’s Zongertinib and Peers
The China’s Center for Drug Evaluation (CDE) website has indicated that several drugs, including German...
HutchMed’s Orpathys Receives Breakthrough Therapy Designation in China for Advanced Lung Cancer
HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) has announced that its MET inhibitor, Orpathys (savolitinib),...
HutchMed to Receive Milestone Payment as Takeda’s Fruzaqla Gets Reimbursement Nod in Spain
China-based HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) is poised to receive another milestone payment...
HutchMed and Innovent Biologics’ Fruzaqla-Tyvyt Combo Gets NMPA Conditional Approval for Endometrial Cancer
Chinese firms HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) and Innovent Biologics, Inc. (HKG: 1801)...
HutchMed Anticipates Milestone Payment as Takeda Launches Fruzaqla in Japan for CRC
China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a milestone payment...
HutchMed to Present Updated Data from Solvleplenib ESLIM-01 Phase III Trial at ASH and ESMO Congress 2024
China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced plans to present new and...
HutchMed to Receive $20 Million Milestone Payment from Takeda for Fruzaqla Sales
China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a USD 20...
HutchMed Halts China Filing for Gastric Cancer Drug Fruquintinib Following Regulatory Feedback
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013), a China-based biopharmaceutical company, has announced the withdrawal...
Hutchmed Withdraws Fruquintinib’s New Indication Application in China, Seeks Alternative Regulatory Path
HONG KONG—Hutchmed (HKG: 0013) has announced its decision to proactively withdraw the new indication application...
HutchMed Establishes Global R&D Hub in Hong Kong Science Park to Accelerate Translational Medicine
HutchMed (NASDAQ: HCM), a China-based biopharmaceutical company, has announced the establishment of a global research...
HutchMed Reports 2024 H1 Financials with Mixed Results Amid Strategic Focus on R&D and Commercial Efficiency
China-based HutchMed (NASDAQ: HCM) has released its financial report for the first half of 2024,...
Takeda Reports Q1 FY2024 Earnings with Growth in Key Therapies and New Launches
Japanese pharmaceutical company Takeda (TYO: 4502, NYSE: TAK) has announced its financial results for the...
HutchMed’s Tazverik for Follicular Lymphoma Accepted for Review by China’s NMPA
HutchMed (NASDAQ: HCM), a China-based biopharmaceutical company, has announced that the National Medical Products Administration...
Takeda’s Fruquintinib for Metastatic Colorectal Cancer Receives European Commission Marketing Approval
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its partner Takeda (TYO: 4502,...
MSD China’s Vaccine Head Tang Xiaochun Departs; HutchMed Welcomes MSD’s Yuan Zezhi as Executive Vice-President
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that Tang Xiaochun, who served as...
HutchMed Initiates Phase I Clinical Trial for HMPL-506 in Hematologic Malignancies
HutchMed (HKG: 0013, NASDAQ: HCM) has announced the commencement of a Phase I clinical study...